Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for severe tophaceous gout
NL-OMON53559Phase 2Withdrawn
- Sponsor
- Jan van Breemen Institute
- Start
- Mar 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rasburicase in gout, sponsored by Jan van Breemen Institute. Primary endpoint: Gout Activity Score. Planned start Mar 2023; status: withdrawn.
02
Drugs
rasburicase
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON53559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53559.